426 related articles for article (PubMed ID: 33314312)
1. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
Kline EM; Houser MC; Herrick MK; Seibler P; Klein C; West A; Tansey MG
Mov Disord; 2021 Jan; 36(1):25-36. PubMed ID: 33314312
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity.
Olsen AL; Feany MB
Neurobiol Dis; 2021 Nov; 159():105482. PubMed ID: 34390834
[TBL] [Abstract][Full Text] [Related]
3. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
4. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease.
Pavlou MAS; Pinho R; Paiva I; Outeiro TF
Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855
[TBL] [Abstract][Full Text] [Related]
5. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
7. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
[TBL] [Abstract][Full Text] [Related]
8. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
[TBL] [Abstract][Full Text] [Related]
9. Gene Dysfunction Mediates Immune Response to Dopaminergic Degeneration in Parkinson's Disease.
Jiao Z; Zhang W; Chen C; Zhu X; Chen X; Zhou M; Peng G; Liu H; Qiu J; Lin Y; Huang S; Mo M; Yang X; Qu S; Xu P
ACS Chem Neurosci; 2019 Feb; 10(2):803-811. PubMed ID: 30289236
[TBL] [Abstract][Full Text] [Related]
10. Immunological Features of LRRK2 Function and Its Role in the Gut-Brain Axis Governing Parkinson's Disease.
Peter I; Strober W
J Parkinsons Dis; 2023; 13(3):279-296. PubMed ID: 37066923
[TBL] [Abstract][Full Text] [Related]
11. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
12. Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
Olsen AL; Clemens SG; Feany MB
Mov Disord; 2023 Feb; 38(2):244-255. PubMed ID: 36416213
[TBL] [Abstract][Full Text] [Related]
13. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
[TBL] [Abstract][Full Text] [Related]
14. Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage.
Franco R; Rivas-Santisteban R; Navarro G; Pinna A; Reyes-Resina I
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924963
[TBL] [Abstract][Full Text] [Related]
15.
Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
[TBL] [Abstract][Full Text] [Related]
16. Sex-dependent interactions between prodromal intestinal inflammation and LRRK2 G2019S in mice promote endophenotypes of Parkinson's disease.
Fang P; Yu LW; Espey H; Agirman G; Kazmi SA; Li K; Deng Y; Lee J; Hrncir H; Romero-Lopez A; Arnold AP; Hsiao EY
Commun Biol; 2024 May; 7(1):570. PubMed ID: 38750146
[TBL] [Abstract][Full Text] [Related]
17. SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
Fernández-Santiago R; Martín-Flores N; Antonelli F; Cerquera C; Moreno V; Bandres-Ciga S; Manduchi E; Tolosa E; Singleton AB; Moore JH; ; Martí MJ; Ezquerra M; Malagelada C
Mov Disord; 2019 Sep; 34(9):1333-1344. PubMed ID: 31234232
[TBL] [Abstract][Full Text] [Related]
18. The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.
Shen Y; Guo X; Han C; Wan F; Ma K; Guo S; Wang L; Xia Y; Liu L; Lin Z; Huang J; Xiong N; Wang T
Cell Mol Life Sci; 2017 Oct; 74(20):3741-3768. PubMed ID: 28623510
[TBL] [Abstract][Full Text] [Related]
19. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains.
Mokretar K; Pease D; Taanman JW; Soenmez A; Ejaz A; Lashley T; Ling H; Gentleman S; Houlden H; Holton JL; Schapira AHV; Nacheva E; Proukakis C
Brain; 2018 Aug; 141(8):2419-2431. PubMed ID: 29917054
[TBL] [Abstract][Full Text] [Related]
20. Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.
Donahue EK; Murdos A; Jakowec MW; Sheikh-Bahaei N; Toga AW; Petzinger GM; Sepehrband F
Mov Disord; 2021 May; 36(5):1126-1136. PubMed ID: 33470460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
